Pfizer and MorphoSys extend Ab development accord
German drugmaker MorphoSys AG says that its antibody development deal with US drug giant Pfizer will be extended until 2011. The revised agreement also allows Pfizer to begin new therapeutic antibody projects with MorphoSys during the life span of the accord.
The original deal, which was signed in December 2003 (Marketletters passim), granted the US firm access to MorphoSys' HuCAL Gold antibody technology library for the selection and optimization of fully-human antibodies against known disease targets. The German firm said that, under the new deal, it stands to receive additional research funding, as well as extra milestone and royalty payments, on any products which are successfully developed. Financial terms of the deal were not provided.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze